The text starts here.

News Release

December 8, 2005
For Print (PDF 98KB)

Eisai Commences U.S. Legal Action over Aricept(R) ANDA Filing

Teaneck, N.J., December 7, 2005 - Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) today announce the filing of a patent infringement lawsuit against Teva* regarding its submission of an abbreviated new drug application (ANDA) to the FDA for Aricept(R) (Active Ingredient Name: donepezil hydrochloride).  Eisai's action was filed in the U.S. District Court for the District of New Jersey in Newark.

Eisai believes that its donepezil composition of matter patent is valid until its expiration date of November 25, 2010. Eisai intends to vigorously enforce and defend that patent.

Aricept(R), a novel acetylcholinesterase inhibitor developed by Eisai Co., Ltd. in Japan, increases the concentration of acetylcholine, a neurotransmitter in the brain. Aricept(R) is currently indicated for the treatment of mild to moderate Alzheimer's disease and is marketed in 76 countries worldwide.

Eisai's corporate human health care (hhc) mission is to give first thought to patients and their families, and to increasing the benefits that health care provides. The company believes that increasing patient satisfaction through the development of innovative new medicines exemplifies its important mission.
Teva Pharmaceuticals USA (Headquarters: Pennsylvania) and its parent company Teva Pharmaceutical Industries, Ltd. (Headquarters: Israel)

Corporate Communications Department
Eisai Co., Ltd.
TEL: 81-3-3817-5120
Cathy Pollini
Corporate Public Relations
Eisai Inc.
TEL: 1-201-287-2052